TUMORI, vol.89, no.2, pp.141-145, 2003 (SCI-Expanded)
Aims and background: We evaluated the efficacy and tolerability of weekly irinotecan as a second-line treatment in patients with colorectal cancer failing 5-fluorouracil-based chemotherapy and searched for predictive and prognostic factors.